PD Theranostics (PDTx) leverages proprietary workflows and methods utilizing imaging-based methodologies to diagnose and guide clinical decision making around specific targeted therapies and their efficacy in human disease states, including cancer, infectious diseases and complications of diabetes including diabetic foot ulcers

This will drive the development of an artificial intelligence (AI) driven theranostic that will guide both diagnostic and therapeutic decision making – involving the use of both unique tissue preparation kits and novel algorithms.

PD Theranostics at-a-glance

Lead Theranostics Artificial Intelligence (AI) driven therapeutic decision-making tool
  • Developing algorithms in prostate cancer (PCa) and diabetic foot ulcers (DFUs) to help choose optimal treatment for a patient
  • License and Sponsored Research Agreements in process with the Vaccine and Immunotherapy Center (VIC) at the Massachusetts General Hospital of Harvard University
  • Initial proof of concept completed in PCa & DFU
  • Enhanced algorithms to be developed; team assembled, including experienced AI leadership
  • Acquired a Hyperion Imaging Mass Cytometry device